<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Mutations in the LCAT gene cause lecithin:cholesterol acyltransferase (LCAT) deficiency, a very rare <z:e sem="disease" ids="C0025517" disease_type="Disease or Syndrome" abbrv="">metabolic disorder</z:e> with 2 hypoalphalipoproteinemia syndromes: classic familial <z:e sem="disease" ids="C0268239" disease_type="Disease or Syndrome" abbrv="">LCAT deficiency</z:e> (Online Mendelian <z:hpo ids='HP_0000005'>Inheritance</z:hpo> in Man No. 245900), characterized by complete lack of enzyme activity, and <z:e sem="disease" ids="C0342895" disease_type="Disease or Syndrome" abbrv="FED">fish-eye disease</z:e> (Online Mendelian <z:hpo ids='HP_0000005'>Inheritance</z:hpo> in Man No. 136120), with a partially defective enzyme </plain></SENT>
<SENT sid="1" pm="."><plain>Theoretically, <z:e sem="disease" ids="C0473527" disease_type="Disease or Syndrome" abbrv="">hypoalphalipoproteinemia</z:e> cases with <z:e sem="disease" ids="C0268239" disease_type="Disease or Syndrome" abbrv="">LCAT deficiency</z:e> should be at increased cardiovascular risk because of <z:chebi fb="6" ids="39025">high-density lipoprotein</z:chebi> deficiency and defective reverse cholesterol transport </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS AND RESULTS: The extent of preclinical <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> was assessed in 40 carriers of LCAT gene mutations from 13 Italian families and 80 healthy controls by measuring carotid intima-media thickness (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMT</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>The average and maximum <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMT</z:e> values in the carriers were 0.07 and 0.21 mm smaller than in controls (P=0.0003 and P=0.0027), respectively </plain></SENT>
<SENT sid="4" pm="."><plain>Moreover, the <z:hpo ids='HP_0000005'>inheritance</z:hpo> of a mutated LCAT genotype had a remarkable gene-dose-dependent effect in reducing carotid <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMT</z:e> (P=0.0003 for average <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMT</z:e>; P=0.001 for maximum <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMT</z:e>) </plain></SENT>
<SENT sid="5" pm="."><plain>Finally, no significant difference in carotid <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMT</z:e> was found between carriers of LCAT gene mutations that cause total or partial <z:e sem="disease" ids="C0268239" disease_type="Disease or Syndrome" abbrv="">LCAT deficiency</z:e> (ie, familial <z:e sem="disease" ids="C0268239" disease_type="Disease or Syndrome" abbrv="">LCAT deficiency</z:e> or <z:e sem="disease" ids="C0342895" disease_type="Disease or Syndrome" abbrv="FED">fish-eye disease</z:e>) </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSIONS: Genetically determined low LCAT activity in Italian families is not associated with enhanced preclinical <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> despite low <z:chebi fb="1" ids="47775">high-density lipoprotein cholesterol</z:chebi> levels </plain></SENT>
<SENT sid="7" pm="."><plain>This finding challenges the notion that LCAT is required for effective atheroprotection and suggests that elevating LCAT expression or activity is not a promising therapeutic strategy to reduce cardiovascular risk </plain></SENT>
</text></document>